Literature DB >> 27394070

Contingency Management Interventions for HIV, Tuberculosis, and Hepatitis Control Among Individuals With Substance Use Disorders: A Systematized Review.

Evan S Herrmann1, Alexis K Matusiewicz2, Maxine L Stitzer3, Stephen T Higgins4, Stacey C Sigmon4, Sarah H Heil4.   

Abstract

Hepatitis, HIV and tuberculosis are significant and costly public health problems that disproportionately affect individuals with substance use disorders (SUDs). Incentive-based treatment approaches (i.e., contingency management; CM) are highly effective at reducing drug use. The primary aim of this report is to review the extant literature that examines the efficacy of CM interventions for the prevention, diagnosis and treatment of hepatitis, HIV and tuberculosis among individuals with SUDs. A literature search identified 23 controlled studies on this topic. In approximately 85% of the studies, CM produced significantly better adherence to prevention, diagnosis and treatment-related medical services, with adherence rates averaging almost 35% higher among patients receiving incentives vs. control condition participants. Findings from these studies parallel the results of a meta-analysis of CM interventions for the treatment of SUDs. The results also suggest that the principles that underlie the efficacy of CM generalize across infectious disease and substance abuse treatment behaviors. The application of additional principles from the literature on CM for treatment of SUDs to interventions targeting infectious disease control would be beneficial. Further development and dissemination of these interventions has the potential to greatly impact public health.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Contingency management intervention; HIV; Hepatitis; Incentives; Substance abuse disorder; Tuberculosis

Mesh:

Year:  2016        PMID: 27394070      PMCID: PMC5386179          DOI: 10.1016/j.jsat.2016.06.009

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  72 in total

Review 1.  A review of delay-discounting research with humans: relations to drug use and gambling.

Authors:  Brady Reynolds
Journal:  Behav Pharmacol       Date:  2006-12       Impact factor: 2.293

2.  A clinical trial of a financial incentive to go to the tuberculosis clinic for isoniazid after release from jail.

Authors:  M C White; J P Tulsky; P Reilly; H W McIntosh; T M Hoynes; J Goldenson
Journal:  Int J Tuberc Lung Dis       Date:  1998-06       Impact factor: 2.373

Review 3.  Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.

Authors:  Paul K Nelson; Bradley M Mathers; Benjamin Cowie; Holly Hagan; Don Des Jarlais; Danielle Horyniak; Louisa Degenhardt
Journal:  Lancet       Date:  2011-07-27       Impact factor: 79.321

4.  Sharing of drug preparation equipment as a risk factor for hepatitis C.

Authors:  H Hagan; H Thiede; N S Weiss; S G Hopkins; J S Duchin; E R Alexander
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

5.  An experimental comparison of three different schedules of reinforcement of drug abstinence using cigarette smoking as an exemplar.

Authors:  J M Roll; S T Higgins; G J Badger
Journal:  J Appl Behav Anal       Date:  1996

6.  Impact of monetary incentives on adherence to referral for screening chest x-rays after syringe exchange-based tuberculin skin testing.

Authors:  David C Perlman; Patricia Friedmann; Leslie Horn; Anne Nugent; Veronika Schoeb; Jeanne Carey; Nadim Salomon; Don C Des Jarlais
Journal:  J Urban Health       Date:  2003-09       Impact factor: 3.671

7.  The emergence of meticillin-resistant Staphylococcus aureus among injecting drug users.

Authors:  S R Atkinson; J Paul; E Sloan; S Curtis; R Miller
Journal:  J Infect       Date:  2009-03-17       Impact factor: 6.072

8.  Use of contingency management incentives to improve completion of hepatitis B vaccination in people undergoing treatment for heroin dependence: a cluster randomised trial.

Authors:  Tim Weaver; Nicola Metrebian; Jennifer Hellier; Stephen Pilling; Vikki Charles; Nicholas Little; Dilkushi Poovendran; Luke Mitcheson; Frank Ryan; Owen Bowden-Jones; John Dunn; Anthony Glasper; Emily Finch; John Strang
Journal:  Lancet       Date:  2014-04-08       Impact factor: 79.321

9.  Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients.

Authors:  P Bruggmann; L Falcato; S Dober; B Helbling; O Keiser; F Negro; D Meili
Journal:  J Viral Hepat       Date:  2008-07-10       Impact factor: 3.728

10.  Prize reinforcement contingency management for treating cocaine users: how low can we go, and with whom?

Authors:  Nancy M Petry; Jacqueline Tedford; Mark Austin; Charla Nich; Kathleen M Carroll; Bruce J Rounsaville
Journal:  Addiction       Date:  2004-03       Impact factor: 6.526

View more
  7 in total

Review 1.  Contingency Management: New Directions and Remaining Challenges for An Evidence-Based Intervention.

Authors:  Carla J Rash; Maxine Stitzer; Jeremiah Weinstock
Journal:  J Subst Abuse Treat       Date:  2016-09-28

2.  Assessing the Use and Impact of Points and Rewards across Four Federal Probation Districts: A Contingency Management Approach.

Authors:  Lincoln Sloas; Amy Murphy; Alese Wooditch; Faye S Taxman
Journal:  Vict Offender       Date:  2019-09-03

3.  Contingency Management and SARS-CoV-2 Testing Among People Who Inject Drugs.

Authors:  Camille C Cioffi; Derek Kosty; Christopher G Capron; Hannah F Tavalire; Robert C Barnes; Anne Marie Mauricio
Journal:  Public Health Rep       Date:  2022-03-03       Impact factor: 3.117

4.  Prescribing Opioids as an Incentive to Retain Patients in Medical Care: A Qualitative Investigation into Clinician Awareness and Perceptions.

Authors:  Kasey R Claborn; Elizabeth R Aston; Jane Champion; Kate M Guthrie
Journal:  J Assoc Nurses AIDS Care       Date:  2018-06-05       Impact factor: 1.354

5.  Self-efficacy as a mediator of patient navigation interventions to engage persons living with HIV and substance use.

Authors:  Sharleen M Traynor; Lisa R Metsch; Lauren Gooden; Maxine Stitzer; Tim Matheson; Susan Tross; Adam W Carrico; Mamta K Jain; Carlos Del Rio; Daniel J Feaster
Journal:  Drug Alcohol Depend       Date:  2021-02-03       Impact factor: 4.492

6.  A SMARTTT approach to Treating Tobacco use disorder in persons with HIV (SMARTTT): Rationale and design for a hybrid type 1 effectiveness-implementation study.

Authors:  E Jennifer Edelman; James Dziura; Yanhong Deng; Krysten W Bold; Sean M Murphy; Elizabeth Porter; Keith M Sigel; Jessica E Yager; David M Ledgerwood; Steven L Bernstein
Journal:  Contemp Clin Trials       Date:  2021-03-29       Impact factor: 2.226

Review 7.  Overview of systematic reviews on strategies to improve treatment initiation, adherence to antiretroviral therapy and retention in care for people living with HIV: part 1.

Authors:  Lawrence Mbuagbaw; Anisa Hajizadeh; Annie Wang; Dominik Mertz; Daeria O Lawson; Marek Smieja; Anita C Benoit; Elizabeth Alvarez; Lisa Puchalski Ritchie; Beth Rachlis; Carmen Logie; Winston Husbands; Shari Margolese; Babalwa Zani; Lehana Thabane
Journal:  BMJ Open       Date:  2020-09-23       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.